ArticleGenes, chromosomes & cancer2026
Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.
Article in Genes, chromosomes & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.Cancers · 2026Review
- Comprehensive analysis ofJournal of thoracic disease · 2026Article
- Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.Genes, chromosomes & cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough TP53 and RB1 co-alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co-alteration are lacking. We performed a pan-cancer analysis to characterize the biology of TP53/RB1 co-alterations and identify therapeutic strategies.
methodsWe analyzed mutation data and copy number variation (CNV) data from 42 371 pan-cancer samples across 26 cancer types from the cBioPortal database. Among them, 2417 tumors with TP53/RB1 co-alterations were used for further analysis. We characterized their epidemiology and molecular biology. Therapeutic vulnerabilities of co-altered tumors were examined using Cancer Cell Line Encyclopedia drug screening datasets.
resultsTP53/RB1 co-alterations occurred in 5.70% of pan-cancer cases but exhibit striking heterogeneity across cancer types. Patients harboring co-alterations had significantly shorter overall survival (OS) in both primary and metastatic settings and poorer response to immune checkpoint inhibitors. Co-altered tumors displayed frequent alterations in chromatin remodeling genes (CREBBP, ARID1A, and KMT2D) and PI3K pathway (PIK3CA and PTEN), but with distinct tissue-specific mutational patterns: EGFR mutations dominated in lung adenocarcinoma (52%), KRAS in pancreatic cancer (88%), and APC in colorectal cancer (77%). Moreover, upregulated genes in co-altered tumors enriched in cell cycle pathways, DNA repair, and neuronal development, whereas immune/inflammatory signaling was suppressed. Critically, drug screening revealed that co-altered tumors showed increased sensitivity to CDK, AURKA, and PI3K/mTOR inhibitors, but resistance to MAPK/ERK pathway inhibitors.
conclusionsTP53/RB1 co-alterations define an aggressive cancer subset with dysregulated cell cycle/chromatin pathways and reduced immunotherapy response. Targeting CDK, AURKA, or PI3K signaling offers promising therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.